Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 13/20 | 0.60 |
| ▸ | DDR1 | Q08345 | 10/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.59 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.59 |
| ▸ | ABL1 | P00519 | 5/20 | 0.56 |
| ▸ | BCR | P11274 | 2/20 | 0.56 |
| ▸ | BRAF | P15056 | 2/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.55 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.55 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.55 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
| ▸ | KIT | P10721 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12871396 | 0.91 | DDR2 (0.63) | DDR2DDR1HIF1AEPAS1ABL1 | |
| SCHEMBL22025455 | 0.90 | DDR2 (0.65) | DDR2DDR1ABL1BCRNTRK1 | |
| SCHEMBL4467208 | 0.89 | DDR2 (0.59) | DDR2DDR1HIF1AEPAS1ABL1 | |
| SCHEMBL13219956 | 0.86 | DDR2 (0.61) | DDR2DDR1HIF1AEPAS1ABL1 | |
| SCHEMBL13772007 | 0.83 | DDR2 (0.56) | DDR2DDR1HIF1AEPAS1ABL1 | |
| SCHEMBL2967106 | 0.83 | DDR1 (0.78) | DDR2DDR1ABL1BCRNTRK1 | |
| SCHEMBL13659892 | 0.82 | BRAF (0.62) | DDR2DDR1BRAFNTRK1NTRK3 | |
| SCHEMBL4255712 | 0.81 | KIT (0.64) | DDR1ABL1BCRBRAFKIT | |
| SCHEMBL13765912 | 0.81 | DDR1 (0.66) | DDR2DDR1ABL1BCRBRAF | |
| SCHEMBL22025464 | 0.80 | P2RX1 (0.59) | ABL1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589101-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2009-09-15 | — | — | US | claimed |
| US-20080287432-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-11-20 | — | — | US | claimed |
| EP-1919924-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2008-05-14 | — | — | EP | claimed |
| WO-2007022268-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-02-22 | — | — | WO | claimed |
| US-7589101-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2009-09-15 | — | — | US | disclosed |
| US-20080287432-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-11-20 | — | — | US | disclosed |
| EP-1919924-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007022268-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287432-A1 | Compounds and Compositions as Protein Kinase Inhibitors | AURKC, PTK2B, FRK | DDR2 222/4885DDR1 312/4885HIF1A 3025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.